Delek Group’s AbbVie ABBV Stock Holding History

Delek Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-325	Closed	-$31K	–	237
2017 Q4	$31K	Buy	+325	New	+$30.6K	﹤0.01%	269

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Delek Group's ABBV Position: Q1 2018 in Review

Delek Group sold out of AbbVie (ABBV) in Q1 2018, closing a stake of 325 shares — an estimated $31K sold.

Delek Group first reported a position in ABBV in Q4 2017 and held it in 1 quarter. The position peaked at $31K in Q4 2017. 2,016 funds tracked by Wall St. Rank hold ABBV as of Q1 2018.

Delek Group reported no remaining AbbVie position as of Q1 2018 after selling out during the quarter.
Delek Group sold 325 AbbVie shares in Q1 2018, an estimated $31K.
Delek Group first reported a position in AbbVie in Q4 2017 and held it in 1 quarter.
Delek Group's AbbVie position peaked at $31K in Q4 2017.
2,016 funds tracked by Wall St. Rank held AbbVie as of Q1 2018.

Based on Delek Group's 13F filing for Q1 2018, filed 15 May 2018.